• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Concordia Provides Update on Long-Term Growth Strategy

    Bryan Mc Govern
    Jun. 21, 2017 09:09AM PST
    Pharmaceutical Investing

    Concordia International shared an update on the company’s long-term plans.

    Concordia International (NASDAQ:CXRX; TSX:CXR) shared an update on the company’s long-term plans.
    As quoted in the press release:

    Further to previous communications, the Company’s development of a long-term growth strategy is nearing completion. Once finalized, the Company intends to communicate its details with stakeholders in the second half of 2017.
    To support the development and execution of this strategy, the Company has engaged Perella Weinberg Partners LP to provide financial advisory services. These services may include, but are not limited to, helping the Company explore and evaluate potential transactional alternatives, including initiatives to optimize its capital structure.
    There can be no assurance that this process will result in any transaction, or that any transaction, if pursued, will be consummated. The Company does not expect to comment further unless and until a specific transaction is approved by its Board of Directors or the Company otherwise decides further disclosure is appropriate or required.
    “We have made significant progress on our long-term growth strategy and we are looking forward to working with Perella Weinberg Partners to support the Company in finalizing and executing on that strategy,” said Allan Oberman, Chief Executive Officer of Concordia International Corp.

    Click here to read the full press release.

    Source: www.newswire.ca

    pharmaceutical investingconcordia internationalboard of directors
    The Conversation (0)

    Go Deeper

    AI Powered

    BCE outlines strategic plan to drive sustainable free cash flow growth and long-term shareholder value

    Osisko Development Announces Further Upsize of Previously Announced "Bought Deal" Offering

    Osisko Development Announces Further Upsize of Previously Announced "Bought Deal" Offering

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Invion Limited

    IVX:AU

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES